アルツハイマー病における中側側頭葉の急激に進行する縮
K A Jobst1, A D Smith, M Szatmari
1University Department of Pharmacology, Radcliffe Infirmary, Oxford, UK.
Lancet (London, England)
|April 2, 1994
まとめ
アルツハイマー病は,年間15.1%の急速な中間側頭葉縮を引き起こし,通常の老化率 (1.5%) を大幅に上回ります. これは,アルツハイマー病は加速老化ではなく,独特の疾患プロセスであることを示唆しています.
科学分野:
- 神経学 神経学とは
- 神経科学は神経科学である.
- ゲロントロジーはゲロントロジーの学科です.
背景:
- アルツハイマー病 (Alzheimer's disease,AD) は,中側側頭葉のニューロン喪失と病理学的変化によって特徴付けられています.
- アルツハイマー病における脳縮の速度を理解することは,正常な老化と区分する上で極めて重要です.
研究 の 目的:
- アルツハイマー病が確認された患者の中側側頭葉縮の割合を定量化するために.
- アルツハイマー病患者の縮率と,健康な高齢者の縮率を比較する.
主な方法:
- 軟骨縮小を測定するために,年1回の側頭葉指向型コンピュータトモグラフィー (CT) スキャンが使用されました.
- この研究では,ヒト病理学的にアルツハイマー病が確認された20人の患者と47人の健康な対照群を対象とした.
主要な成果:
- アルツハイマー病の患者は,年間15.1%の平均の中間側頭葉縮率を示した.
- 健康的な加齢による対照群では,アトロフィー率が年間1.5%と著しく低いことが示されました.
結論:
- アルツハイマー病における過度の中間側頭葉縮は,ユニークな病理学的プロセスを示唆しています.
- アルツハイマー病は,正常な老化の加速ではなく,明らかに病気のプロセスである可能性が高い.
関連する概念動画
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...